University of Rochester NCORP Research Base
Trial Pipeline
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
NCT04829539
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
NCT05364086
Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy
NCT04888988
Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer and Their Caregivers
NCT04062552
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
NCT03996265
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
NCT03367572
Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer
NCT03186638
Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy in Reducing Insomnia in Cancer Survivors
NCT02613364
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 3 |
Therapeutic Areas
What the Pipeline for University of Rochester NCORP Research Base Shows
According to the ClinicalTrials.gov registry, University of Rochester NCORP Research Base is linked to 8 US clinical trials across every stage of research activity. Of those, 1 studies are currently recruiting — about 13% of the sponsor's indexed portfolio — and 3 are already marked complete, representing roughly 38% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for University of Rochester NCORP Research Base reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for University of Rochester NCORP Research Base is Malignant Solid Neoplasm with 4 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.